专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2013147504A Method and composition for treatment of disorder associated with chlamydia and similar bacterial infection 审中-公开
标题翻译：治疗与CHLAMYDIA和类似细菌感染相关的疾病的方法和组合
公开(公告)号：JP2013147504A
公开(公告)日：2013-08-01
申请号：JP2013076511
申请日：2013-04-02
申请人： Thomas Julius Borody , トーマスジュリアスボロディー
发明人： BAUMGART KARL WILLIAM , BORODY THOMAS JULIUS
IPC分类号： A61K9/50 , A61K45/06 , A61K9/20 , A61K9/48 , A61K31/015 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/35 , A61K31/42 , A61K31/47 , A61K31/4704 , A61K31/495 , A61K31/496 , A61K31/5383 , A61K31/65 , A61K31/7048 , A61K31/7052 , A61P31/04 , A61P43/00
CPC分类号： A61K45/06
摘要： PROBLEM TO BE SOLVED: To provide a method and a pharmaceutical composition for treatment or prevention of conditions associated with infection by Chlamydia species or similar susceptible microorganisms in a patient in need of such treatment or prevention.SOLUTION: A method for treatment or prevention and a pharmaceutical composition are provided, the treatment or prevention including administering to a patient an effective amount of at least two different antibodies or antimicrobial agents selected from a group consisting of tetracycline, macrolide-based antibiotic, quinolone, chloramphenicol, rifamycin, sulfonamide drug, co-trimoxazoele and oxazolidinone.
摘要翻译：要解决的问题：提供用于治疗或预防与需要这种治疗或预防的患者中的衣原体物种或类似的易感微生物感染相关的病症的方法和药物组合物。解决方案：一种治疗或预防的方法和提供药物组合物，包括给患者施用有效量的至少两种不同的抗体或选自四环素，大环内酯类抗生素，喹诺酮，氯霉素，利福霉素，磺酰胺药物，三唑并恶唑烷酮。

2. 发明专利

JP2010174030A Method and composition for treatment of disorders associated with chlamydia and similar bacterial infection 有权
标题翻译：用于治疗与CHLAMYDIA和类似细菌感染有关的疾病的方法和组合
公开(公告)号：JP2010174030A
公开(公告)日：2010-08-12
申请号：JP2010074109
申请日：2010-03-29
申请人： Thomas Julius Borody , トーマスジュリアスボロディー
发明人： BAUMGART KARL WILLIAM , BORODY THOMAS JULIUS
IPC分类号： A61K9/50 , A61K31/165 , A61K31/015 , A61K31/16 , A61K31/18 , A61K31/35 , A61K31/395 , A61K31/42 , A61K31/421 , A61K31/47 , A61K31/4704 , A61K31/495 , A61K31/496 , A61K31/65 , A61K31/7048 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P9/00 , A61P9/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/02 , A61P15/00 , A61P25/28 , A61P31/04 , A61P35/00 , A61P43/00
CPC分类号： A61K45/06
摘要： PROBLEM TO BE SOLVED: To provide a method and a pharmaceutical composition for treatment or prevention of conditions associated with infection by Chlamydia species or similar susceptible microorganisms in a patient in need of such treatment or prevention. SOLUTION: The pharmaceutical composition comprises at least two different antibodies or antimicrobial agents selected from the group consisting of tetracycline, macrolide-based antibiotic, quinolone, chloramphenicol, rifamycin, sulfonamide drug, co-trimoxazoele and oxazolidinone. The method for treatment or prevention comprises the administration to the patient of an effective amount of the pharmaceutical composition. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供用于治疗或预防与需要这种治疗或预防的患者中衣原体物种或类似的易感微生物感染有关的病症的方法和药物组合物。解决方案：药物组合物包含至少两种不同的抗体或选自四环素，大环内酯类抗生素，喹诺酮，氯霉素，利福霉素，磺酰胺药物，复方异恶唑和恶唑烷酮的抗微生物剂。治疗或预防的方法包括向患者施用有效量的药物组合物。版权所有（C）2010，JPO＆INPIT

3. 发明授权

US11612635B2 Enteric combination therapy 有权
公开(公告)号：US11612635B2
公开(公告)日：2023-03-28
申请号：US17715009
申请日：2022-04-06
申请人： Thomas Julius Borody
发明人： Thomas Julius Borody
IPC分类号： A61K38/14 , A61K31/4184 , A61K31/165 , A61K31/166 , A61K31/485 , A61K31/496 , A61K31/7036 , A61K31/7048 , A61K31/4178 , A61K9/00 , A61K9/02 , A61K9/20 , A61K9/48 , A61K31/4188 , A61K31/4025 , A61K31/40 , A61K45/06 , A61K31/4164 , A61K31/437 , A61K31/196 , A61K31/4525
摘要： There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

4. 发明申请

US20200297797A1 NOVEL ENTERIC COMBINATION THERAPY 审中-公开
公开(公告)号：US20200297797A1
公开(公告)日：2020-09-24
申请号：US16799680
申请日：2020-02-24
申请人： Thomas Julius BORODY
发明人： Thomas Julius BORODY
IPC分类号： A61K38/14 , A61K9/00 , A61K31/165 , A61K9/02 , A61K9/48 , A61K9/20
摘要： There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

5. 发明授权

US10517922B2 Enteric combination therapy 有权
公开(公告)号：US10517922B2
公开(公告)日：2019-12-31
申请号：US15794819
申请日：2017-10-26
申请人： Thomas Julius Borody
发明人： Thomas Julius Borody
IPC分类号： A61K38/14 , A61K31/165 , A61K31/4164 , A61K31/4178 , A61K31/4184 , A61K31/166 , A61K31/485 , A61K31/496 , A61K31/7036 , A61K31/7048 , A61K45/06 , A61K31/437 , A61K31/196 , A61K31/4525
摘要： There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

6. 发明申请

US20160151432A1 PROBIOTIC RECOLONISATION THERAPY 有权
公开(公告)号：US20160151432A1
公开(公告)日：2016-06-02
申请号：US15017376
申请日：2016-02-05
申请人： Thomas Julius BORODY
发明人： Thomas Julius BORODY
IPC分类号： A61K35/742 , A61K9/48 , A23C9/13 , A61K31/341 , A61K38/14 , A61K35/741 , A61K9/50
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

7. 发明申请

US20160151431A1 PROBIOTIC RECOLONISATION THERAPY 有权
公开(公告)号：US20160151431A1
公开(公告)日：2016-06-02
申请号：US15017372
申请日：2016-02-05
申请人： Thomas Julius BORODY
发明人： Thomas Julius BORODY
IPC分类号： A61K35/742 , A61K9/48 , A23C9/123 , A61K31/341 , A61K38/14 , A61K35/741 , A61K9/50
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

8. 发明授权

US09320763B2 Probiotic recolonisation therapy 有权
标题翻译：益生菌再殖民治疗
公开(公告)号：US09320763B2
公开(公告)日：2016-04-26
申请号：US14793630
申请日：2015-07-07
申请人： Thomas Julius Borody
发明人： Thomas Julius Borody
IPC分类号： A61K39/00 , A61K39/38 , A61K39/02 , A61K39/08 , A61K39/108 , A61K35/24 , A61K35/74 , A61K38/48 , A23L1/30 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
摘要翻译：本发明涉及适用于治疗与在哺乳动物宿主的胃肠道中存在异常或异常分布的微生物群落有关的慢性疾病的药物组合物，该组合物包含活的非致病性或减毒的病原性梭菌。所述组合物还包含选自拟杆菌属，真细菌属，细菌杆菌属，丙酸杆菌属，乳杆菌属，厌氧球菌，球菌属，大肠杆菌，Gemmiger，Desulfomonas，消化链球菌和真菌的一种或多种另外的活的非致病或减毒病原微生物。本发明还提供适用于治疗相同慢性疾病的药物组合物，其包含活的非致病性或减毒致病性大肠杆菌，至少一种活的非致病性或减毒致病性拟杆菌菌株和至少一种存活的非致病性菌株或减毒病原微生物。

9. 发明授权

US09050358B2 Compositions and methods for probiotic recolonization therapies 有权
标题翻译：益生菌再结扎治疗的组合和方法
公开(公告)号：US09050358B2
公开(公告)日：2015-06-09
申请号：US14270034
申请日：2014-05-05
申请人： Thomas Julius Borody
发明人： Thomas Julius Borody
IPC分类号： A61K39/08 , A61K39/00 , A61K39/38 , A61K39/116 , A61K39/09 , A01N63/00 , A01N65/00 , A61K38/48 , A23L1/30 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/74
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
摘要翻译：本发明涉及适用于治疗与在哺乳动物宿主的胃肠道中存在异常或异常分布的微生物群落有关的慢性疾病的药物组合物，该组合物包含活的非致病性或减毒的病原性梭菌。所述组合物还包含选自拟杆菌属，真细菌属，细菌杆菌属，丙酸杆菌属，乳杆菌属，厌氧球菌，球菌属，大肠杆菌，Gemmiger，Desulfomonas，消化链球菌和真菌的一种或多种另外的活的非致病或减毒病原微生物。本发明还提供适用于治疗相同慢性疾病的药物组合物，其包含活的非致病性或减毒致病性大肠杆菌，至少一种活的非致病性或减毒致病性拟杆菌菌株和至少一种存活的非致病性菌株或减毒病原微生物。

10. 发明授权

US09040036B2 Compositions for probiotic recolonisation therapy 有权
标题翻译：益生菌再殖药治疗的组合
公开(公告)号：US09040036B2
公开(公告)日：2015-05-26
申请号：US13910579
申请日：2013-06-05
申请人： Thomas Julius Borody
发明人： Thomas Julius Borody
IPC分类号： A01N63/00 , A01N65/00 , A61K39/08 , A23L1/30 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/74
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
摘要翻译：本发明涉及适用于治疗与在哺乳动物宿主的胃肠道中存在异常或异常分布的微生物群落有关的慢性疾病的药物组合物，该组合物包含活的非致病性或减毒的病原性梭菌。组合物还包含一种或多种另外的活的非致病性或减毒性病原微生物，其选自拟杆菌属，真细菌属，细菌杆菌属，丙酸杆菌属，乳杆菌属，厌氧球菌属，红球菌属，大肠杆菌属，Gemmiger，Desulfamonas，消化链球菌属和真菌。本发明还提供了适用于治疗相同慢性疾病的药物组合物，其包含活的非致病性或减毒致病性大肠杆菌，至少一种活的非致病性或减毒病原性拟杆菌菌株和至少一种存活的非致病性菌株或减毒病原微生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式